Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 May 14;3:e28835. doi: 10.4161/onci.28835

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Landes Bioscience

This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

PMC Copyright notice

graphic file with name onci-3-e28835-g1.jpg — Figure 1. The strategy to eradicate AML cells via chimeric antigen-receptor (CAR) immunotherapy. Chimeric antigen receptor (CAR) engineered cytokine-induced killer (CIK) T cells specifically target acute myeloid leukemia (AML) surface antigen by exploiting the antigen binding properties of CD123-CAR activating CIK cytotoxic effector functions to specifically eliminate malignant cells while sparing the normal hematopoietic stem/progenitor (HSPC) counterpart.